Author: James, Joe; Jose, James; Gafoor, V. Abdul; Smita, B; Balaram, Neetha
Title: Guillainâ€Barré syndrome following ChAdOx1 nCoVâ€19 COVIDâ€19 vaccination: A case series Cord-id: fh5s1s4p Document date: 2021_7_21
ID: fh5s1s4p
Snippet: ChAdOx1 nCoVâ€19 is an effective and wellâ€tolerated coronavirus disease 2019 (COVIDâ€19) vaccine. Rare cases of serious adverse events have been reported with this vaccine. We report three patients who developed Guillainâ€Barré syndrome following ChAdOx1 nCoVâ€19 vaccination, who did not have active or prior COVIDâ€19 infection. The neurological illness in all patients had an onset of 11â€13 days after the first dose of vaccine. All were characterized by sensorimotor weakness of the upp
Document: ChAdOx1 nCoVâ€19 is an effective and wellâ€tolerated coronavirus disease 2019 (COVIDâ€19) vaccine. Rare cases of serious adverse events have been reported with this vaccine. We report three patients who developed Guillainâ€Barré syndrome following ChAdOx1 nCoVâ€19 vaccination, who did not have active or prior COVIDâ€19 infection. The neurological illness in all patients had an onset of 11â€13 days after the first dose of vaccine. All were characterized by sensorimotor weakness of the upper and lower limbs, with facial diplegia in one and dysautonomia in the other. Nerve conduction studies were consistent with demyelination in two and axonopathy in one. Cerebrospinal fluid analysis showed albuminocytological dissociation in two patients. All patients had moderateâ€toâ€severe disability. They were treated with intravenous immunoglobulin, with stabilization of the disease. Proper monitoring and prompt reporting of such cases is required to ensure safety of the vaccine.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date